AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06720909 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Open-Label Placebo (OLP)
Description: The placebo pills will be size #1 capsules filled with (1) microcrystalline cellulose, a common inert excipient for pharmaceuticals, and (2) 25 mg riboflavin tracer. Participants will be informed that the placebo pills are inactive substances, like sugar pills, and contain no active medication. Then, they will watch a brief introduction video which will cover four main discussion points: (1) the placebo effect can be powerful and can have beneficial effects for diverse symptoms, (2) the body can respond to taking placebo pills automatically despite the knowledge that it is placebo (e.g., Pavlov's dogs), (3) a positive attitude or expectation can be beneficial but is not necessary, and (4) taking the pills faithfully throughout the intervention period is critical.
Study NCT06720909 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MBSR+OLP
Description: This condition involves a combination of interventions, where participants will receive both MBSR and OLP treatments.
Study NCT06730594 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VL-BK-02 (25 billion CFU/Capsule)
Description: One capsule per day consumed orally before breakfast Duration: 84 days (12 weeks)
Study NCT06730594 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Microcrystalline Cellulose - 375 mg/capsule)
Description: One capsule per day consumed orally before breakfast Duration: 84 days (12 weeks)
Study NCT06704763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orforglipron
Description: Administered orally
Study NCT06704763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Administered orally
Study NCT06704763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinidine
Description: Administered orally
Study NCT06733935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKX019
Description: NKX019 is an investigational allogeneic CD19-Directed CAR NK
Study NCT06733935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepletion
Study NCT06733363 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Dietary Intervention
Description: Participate in POW-R Health Only/Core program
Study NCT06733363 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone- Based Intervention
Description: Receive live phone calls
Study NCT06729450 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DispersinB Acne Cleanser
Description: DispersinB Acne Cleanser, strength: 80 ug/g, topical gel
Study NCT06728462 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Amorphous calcium carbonate
Description: The usual dose for oral use is 5 ACC tablets (equal to 1000 mg calcium element) daily given after meals.
Study NCT06723145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: perioperative aspirin continuation
Study NCT06723145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin interruption
Description: Aspirin interruption 5-7 days before surgery
Study NCT06741111 — intervention group
Intervention type: OTHER
Intervention: No treatment given
Description: No treatment given
Study NCT06736691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: emodepside (BAY 44-4400)
Description: Treatment with single dose of oral 15 mg emodepside
Study NCT06736691 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: matching placebo of emodepside
Description: Treatment with single dose of oral emodepside matching placebo
Study NCT06736691 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mebendazole
Description: Treatment with 100 mg mebendazole orally administered b.i.d. for 3 days
Study NCT06736691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: similar placebo to mebendazole
Description: Treatment with mebendazole similar placebo orally administered b.i.d. for 3 days
Study NCT06736262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Briquilimab
Description: No additional details needed
Study NCT06516965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povorcitinib
Description: Oral Tablet
Study NCT06516965 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Tablet
Study NCT06741228 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A substance that is designed to have no therapeutic value
Study NCT06741228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM120 (LSD D-Tartrate)
Description: A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)
Study NCT06740227 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Virtual Reality-Based Balance Training
Description: Virtual reality workout session will be for about 30-40 minutes Warm-up exercise will be for 5 minutes including relaxed breathing For Static Balance, Lotus Focus, Tree pose, Warrior Pose games will be used For Dynamic Balance, Soccer Heading, Ski Jump, Tight Rope Walk, Table Tilt, Ski Slalom games will be used 5 minutes will be given for cool down.
Study NCT06740227 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Balance Training
Description: one minute of rest for every five minutes of exercise Conventional Balance workout session will be for about 30-40 minutes Warm-up for 5 minutes For Static Balance, Static Balance, Single Leg Standing, Stork Standing will be used For Dynamic Balance, Weight Shifts, Tandem Walk, Single Leg Balance with Arm Movements 5 minutes will be given for cool down
Study NCT06735144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FH-006
Description: Intravenous injection once every two weeks (Q2W), with a treatment period of 28 days
Study NCT06735144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FH-006
Description: administered once every 3 weeks (Q3W), with a treatment period of 21 days
Study NCT06740747 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent theta-burst stimulation
Description: Intermittent theta-burst stimulation, applied sequentially to the cerebellar vermis and the left dorsolateral prefrontal cortex
Study NCT06740747 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham intermittent theta-burst stimulation
Description: Sham intermittent theta-burst stimulation, applied sequentially to the cerebellar vermis and the left dorsolateral prefrontal cortex
Study NCT06740201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cipepofol
Description: Adjust plasma target-controlled concentration
Study NCT06735014 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: Participants will undergo 3T MRI scanning of the brain and cervical spine MRIs
Study NCT06735014 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma neurofilament light chain (NfL) quantification
Description: Participants will undergo a blood draw for the quantification of plasma neurofilament light chain
Study NCT06745557 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: denovoSkin(TM)
Description: Transplantation of autologous dermo-epidermal skin substitute denovoSkin(TM) to the experimental area
Study NCT06745557 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: STSG
Description: Transplantation of autologous split-thickness skin to the control area
Study NCT06742697 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flexibility, Resistance, Aerobic, Movement Execution training
Description: Flexibility: static and dynamic stretching combined with sensory, high-frequency electrical stimulation to reduce spasticity and improve mobility.~Resistance training: core stability and lower limb strength training in conditions of instability, to improve strength, coordination, and balance.~Movement execution training: gait training according to motor learning principles.~Aerobic exercise: in the form of high-intensity interval training at the end of each session, to improve cardiovascular status and foster motor learning consolidation (probably due to the release of brain derived neurothrophic factors).
Study NCT06357091 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACL reconstruction with Shark Screw ACL®
Description: ACL reconstruction with the Shark Screw ACL®, Investigation of tunnel widening
Study NCT06357091 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL reconstruction with biocomposite screw (Mecta)
Description: ACL reconstruction with biocomposite screw (Mecta), Investigation of tunnel widening
Study NCT06072300 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity calorie equivalent labelling
Description: Physical activity calorie equivalent labelling on beverage vending machines
Study NCT06301828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab Injection
Description: Endostar+SBRT+Envafolimab Injection
Study NCT06301828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: Endostar+SBRT+Envafolimab Injection
Study NCT05555797 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 308nm Excimer laser
Description: Excimer laser will be (1-2 sessions/ week for 12 sessions according to induration protocol)
Study NCT05555797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazarotene Topical Gel
Description: Tazarotene gel 0.1%(finger tip unit of the gel) will be applied once daily for weeks
Study NCT05555797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone Valerate
Description: .Betamethasone valerate ointment 0.1% will be applied twice daily for 12 weeks.
Study NCT05751590 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comined use of gliddescope and fiberoptic broncscopy
Description: endotrachotreal intubation will be done by combined use of Glidescope and Fiberoptic broncscopy
Study NCT05751590 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fiberoptic bronscopy
Description: endotrachotreal intubation will be done by Fiberoptic broncscopy
Study NCT06399432 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean Diet
Description: In the Mediterranean Diet, all foods are included. Red meat will be limited to 1/week, poultry to ≤3 times/week and fish to 2-3 times/week. Supplementation with extra-virgin olive oil and nuts, providing 1 liter of olive oil per week and 30 gr a day of nuts.~The dietician will personalize the dietary advice by adapting it to the patient's condition, preferences and beliefs, will encourage adherence, and transmit a sense of empowerment. A change in diet with specific, attainable goals will be negotiated between the dietician and the participant.~Dieticians will conduct a phone call once in every 2-week period to assess dietary compliance using a 24-hour food recall, the Mediterranean Diet Adherence Form. MD patients will keep a diet diary for 3 days every two weeks, which they will discuss with the dietician during their scheduled dietician assessment. The Baseline Visit with the dietician can occur either in-person or via video communication software.
Study NCT05681156 — intervention group
Intervention type: OTHER
Intervention: N/A- There is no intervention.
Description: There is no intervention.
Study NCT06747793 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: The intervention will consist of relaxing virtual reality stimulation, which will be started after obtaining informed consent. Immersive 360-degree videos (nature environments) will be played inside a head-mounted display, with the video sound played inside headphones. Each virtual reality video will last 30 minutes. The stimulation will be provided two times per day, morning and evening, every day until the patient ICU discharge, or the maximum of 7 days will be reached. The intervention group will also receive standard intensive care unit care, same as in the control group.
Study NCT04913181 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Artificial intelligence sepsis prediction model
Description: The main purpose of this paper is to evaluate the accuracy of the sepsis prediction model established in the early stage. The occurrence of sepsis is determined by the daily clinical judgment of doctors, and the results of sepsis prediction model are matched and corrected.
Study NCT06750185 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT317 DL1
Description: Intravenous infusion
Study NCT06750185 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT317 DL2
Description: Intravenous infusion
Study NCT06750185 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT317 DL3
Description: Intravenous infusion
Study NCT06750185 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT317 DL4
Description: Intravenous infusion
Study NCT06750185 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT317 DL5 (intermediate)
Description: Intravenous infusion
Study NCT06750185 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT317 DL6 (intermediate)
Description: Intravenous infusion
Study NCT06750185 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT317 DL7 (additional)
Description: Intravenous infusion
Study NCT06746428 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Coaching
Description: An exercise coaching program tailored for women with Stage I-IVA endometrial cancer who have undergone total or modified radical hysterectomy with surgical staging. The intervention targets a total of 8 participants who are planned to complete pelvic external beam radiation therapy as part of their adjuvant treatment.
Study NCT06757036 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Laughter Yoga
Description: the group where Laughter Yoga is performed
Study NCT06749587 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEOSYAL RHA® 1
Description: Product injection in infraorbital hollows~TEOSYAL RHA® 1 is a sterile, transparent, non-pyrogenic, viscoelastic gel made of Hyaluronic Acid (HA) of non-animal origin
Study NCT06752109 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antipronation Taping
Description: Before applying the tape, its length was measured by passing it over the areas on the foot where it would be applied. The tape was first attached to the medial side of the big toe, with tension in the direction of flexion and abduction of the toe. The ankle was then positioned in full plantar flexion. The tape was applied from the medial side of the foot towards the heel, wrapping around it, and then directed towards the sole. While the foot was in an inversion position at the navicular level, the tape was applied with maximum tension from medial to lateral and brought back to the sole. The remainder of the tape, with maximum tension, was applied from the sole to the dorsal side of the ankle, ending without tension at the proximal and lateral side of the leg. A second strip of tape, with maximum tension, was applied to support the medial longitudinal arch. The ends of the tape were placed over the malleoli without tension, aiming to reduce excessive pronation.
Study NCT06752109 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: In the sham taping application, the length of the tape was measured by passing it over the areas where it would be applied. The tape was applied to the medial side of the big toe, but without tension, simply placed. Then, the tape was directed towards the sole of the foot, passing over the heel. At the navicular level, the tape was applied from medial to lateral, returning to the sole without tension. A second strip of tape was applied to the sole without tension. The ends of the tape were placed over the malleoli without stretching. Since no tension was applied, this application was only placed and has a limited effect on reducing excessive pronation.
Study NCT04983485 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Respiratory muscle electromyographic activations of individuals will be evaluated during the test while breathing rapidly and deeply from the beginning of the constant threshold load endurance test and the increasing threshold load endurance test until the end of the test, and at rest. Respiratory muscle endurance will be evaluated with constant threshold load endurance test and increasing threshold load endurance test, respiratory functions with pulmonary function test, respiratory muscle strength with intraoral pressure measurement device, health condition disorder with Chronic Obstructive Pulmonary Disease Assessment Scale, dyspnea with Modified Medical Research Council Dyspnea Scale and Modified Borg Scale. Participants' names, anthropometric measurements, demographic data, contact information and medical history will be collected and recorded with the patient anamnesis form.
Study NCT04183595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (N1, N3-bis(2- mercaptoethyl)isophthalamide)
Description: 600mg / day NBMI treatment for 14 days, administered as four capsules of 100 mg of NBMI every 24 hours, at the start of treatment, the principal investigator or his delegate will verify the intake of the first dose and deliver a blister pack corresponding to the remaining NBMI capsules, at visit day 14 research subjects will be asked to return the packaging with the remaining capsules or not, in order to estimate adherence to treatment.
Study NCT04183595 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Excipients microcrystalline cellulose, silica and magnesium stearate
Description: 6 Capsules will be administered every 24 hours for 14 days.
Study NCT04972708 — intervention group
Intervention type: GENETIC
Intervention: Cross-sectional genetics study
Description: Cross-sectional genetics study
Study NCT06753500 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autonomic neural blockade
Description: Autonomic nerve block performed with:~* Bupivacaine: 20 mL of 0.5%.~* Dexamethasone: 8 mg.
Study NCT04804657 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sage extracts Cognivia
Description: Cognivia is composed of 400 mg of aqueous extract from Salvia officinalis and the remaining 200 mg contained 50 µL of Salvia lavandulaefolia essential oil and encapsulated with gum acacia. It will be administrated the the morning before the endurance test (oral administration).
Study NCT04804657 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Made with maltodextrin. It will be administrated the the morning before the endurance test (oral administration).
Study NCT04885322 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: In tDCS, saline-soaked electrodes are temporary affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (\~20 minutes) to stimulate the targeted brain area. The targeted brain area is determined by the Study Arm.
Study NCT04885322 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: In tDCS, saline-soaked electrodes are temporary affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (\~20 minutes) to stimulate the targeted brain area. The targeted brain area is determined by the Study Arm.
Study NCT06094218 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Cognitive Behavioral Therapy (BCBT)
Description: BCBT was developed to provide patients with the skills they need to better manage the cognitive, emotional, physiological, and behavioral components of acute suicidal crises.
Study NCT06094218 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: Behavioral health treatment as it is typically provided at the treatment site.
Study NCT06434766 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham stimulation
Description: sham theta-burst transcranial magnetic stimulation
Study NCT06434766 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intermittent theta-burst stimulation (iTBS)
Description: intermittent theta-burst transcranial magnetic stimulation
Study NCT06193408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VR-AD-1005
Description: oral capsule
Study NCT06193408 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral capsule
Study NCT04765644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Two 200 mg capsules per day (400 mg/day) for 7 days
Study NCT04765644 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsules/day for 7 days
Study NCT04765644 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: L-arginine + placebo
Description: L-arginine = Five capsules of 2 mg per day (10 mg/day) for 7 days Placebo = 2 capsules/day for 7 days
Study NCT04765644 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: L-arginine + celecoxib
Description: L-arginine = Five capsules of 2 mg per day (10 mg/day) Celecoxib = Two 200 mg capsules per day (400 mg/day) for 7 days
Study NCT06038084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bronpass Tab.
Description: Twice a day
Study NCT06038084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Erdos capsule
Description: Three times a day (It is for the masking.)
Study NCT06038084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erdos capsule
Description: Three times a day
Study NCT06038084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of Bronpass Tab.
Description: Twice a day (It is for the masking.)